NRXS · Neuraxis Inc. Common Stock
View on chartInsiders & Stakes
| Brian Hannasch 10% Owner | ▲ Buy | Open Market | 1,211,522 Shares held | 2/12/2026 | View profile |
| Brian Allen Carrico Chief Executive Officer | ▲ Buy | Open Market | 227,604 Shares held | 10/8/2026 | View profile |
| Thomas Joeseph Carrico CRO, CCO, CPO | ▲ Buy | Open Market | 199,673 Shares held | 10/8/2026 | View profile |
| Miranda Adrian CMO, SVP Science & Tech | ▲ Buy | Grant | 199,106 Shares held | 8/24/2026 | View profile |
| Gil Aharon Director | ▲ Buy | Grant | 80,058 Shares held | 8/13/2026 | View profile |
| Bradley Mitchell Watkins Director | ▲ Buy | Grant | 72,408 Shares held | 8/13/2026 | View profile |
| Jane Elizabeth Keyser Director | ▲ Buy | Grant | 72,408 Shares held | 8/13/2026 | View profile |
| Kristin A. Ferge Director | ▲ Buy | Grant | 67,072 Shares held | 8/13/2026 | View profile |
| Timothy Robert Henrichs Chief Financial Officer | ▲ Buy | Open Market | 9,530 Shares held | 10/8/2026 | View profile |
| MASIMO CORP 10% Owner | ▼ Sell | Open Market | 0 Shares held | 7/1/2025 | View profile |
Transaction History
| Brian Allen Carrico | ▲ Buy | Open Market | 268 | $1K | 10/8/2026 |
| Thomas Joeseph Carrico | ▲ Buy | Open Market | 328 | $2K | 10/8/2026 |
| Timothy Robert Henrichs | ▲ Buy | Open Market | 1,937 | $9K | 10/8/2026 |
| Thomas Joeseph Carrico | ▲ Buy | Grant | 193,678 | — | 8/24/2026 |
| Miranda Adrian | ▲ Buy | Grant | 199,106 | — | 8/24/2026 |
| Brian Allen Carrico | ▲ Buy | Grant | 199,188 | — | 8/24/2026 |
| Kristin A. Ferge | ▲ Buy | Grant | 31,134 | $196K | 8/13/2026 |
| Gil Aharon | ▲ Buy | Grant | 43,930 | $276K | 8/13/2026 |
| Bradley Mitchell Watkins | ▲ Buy | Grant | 26,073 | $164K | 8/13/2026 |
| Jane Elizabeth Keyser | ▲ Buy | Grant | 26,073 | $164K | 8/13/2026 |
| Gil Aharon | ▲ Buy | Grant | 40,068 | — | 7/29/2026 |
| Gil Aharon | ▲ Buy | Grant | 2,226 | — | 7/29/2026 |
| Gil Aharon | ▲ Buy | Grant | 12,304 | — | 4/28/2026 |
| Gil Aharon | ▲ Buy | Grant | 221,917 | — | 4/28/2026 |
| Thomas Joeseph Carrico | ▲ Buy | Open Market | 667 | $1K | 4/1/2026 |
| Brian Allen Carrico | ▲ Buy | Open Market | 8,060 | $16K | 4/1/2026 |
| Timothy Robert Henrichs | ▲ Buy | Open Market | 7,593 | $15K | 4/1/2026 |
| Brian Hannasch | ▲ Buy | Open Market | 40,000 | $197K | 2/12/2026 |
| Brian Hannasch | ▲ Buy | Open Market | 40,000 | $186K | 2/11/2026 |
| Bradley Mitchell Watkins | ▲ Buy | Grant | 21,598 | $100K | 1/22/2026 |
| Jane Elizabeth Keyser | ▲ Buy | Grant | 21,598 | $100K | 1/22/2026 |
| Gil Aharon | ▲ Buy | Grant | 21,598 | $100K | 1/22/2026 |
| Kristin A. Ferge | ▲ Buy | Grant | 21,598 | $100K | 1/22/2026 |
| Gil Aharon | ▲ Buy | Open Market | 286,138 | $1.0M | 12/23/2025 |
| Brian Hannasch | ▲ Buy | Open Market | 355,556 | $800K | 7/1/2025 |
| MASIMO CORP | ▼ Sell | Open Market | 531,548 | $1.2M | 7/1/2025 |
| MASIMO CORP | ▼ Sell | Other | 289,779 | $29 | 7/1/2025 |
| MASIMO CORP | ▼ Sell | Open Market | 289,779 | $652K | 7/1/2025 |
| Brian Hannasch | ▲ Buy | Open Market | 18,065 | $31K | 4/21/2025 |
| Kristin A. Ferge | ▲ Buy | Grant | 13,157 | $37K | 1/17/2025 |
| Jane Elizabeth Keyser | ▲ Buy | Grant | 13,157 | $37K | 1/17/2025 |
| Bradley Mitchell Watkins | ▲ Buy | Grant | 13,157 | $37K | 1/17/2025 |
| Kristin A. Ferge | ▲ Buy | Grant | 1,183 | $0 | 6/28/2024 |
| Jane Elizabeth Keyser | ▲ Buy | Grant | 11,580 | $0 | 6/28/2024 |
| Bradley Mitchell Watkins | ▲ Buy | Grant | 11,580 | $0 | 6/28/2024 |
| Brian Hannasch | ▲ Buy | Grant | 75,000 | $0 | 2/20/2024 |
| Brian Hannasch | ▼ Sell | Other | 150,000 | $0 | 2/6/2024 |
| Brian Hannasch | ▼ Sell | Open Market | 76 | $198 | 12/28/2023 |
| Brian Hannasch | ▼ Sell | Other | 40,000 | $200 | 12/28/2023 |
| MASIMO CORP | ▼ Sell | Other | 531,548 | — | 8/10/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
NeurAxis Names Craig Blanchard CCO to Drive Commercial Growth
NeurAxis has appointed Craig Blanchard as chief commercial officer to lead the next phase of commercial growth. The move signals the company’s focus on expanding market reach and accelerating product commercialization. Blanchard’s experience is expected to help the firm move from development to broader market adoption.
NeurAxis Names Craig Blanchard CCO to Drive Commercial Growth. NeurAxis has appointed Craig Blanchard as chief commercial officer to lead the next phase of commercial growth. The move signals the company’s focus on expanding market reach and accelerating product commercialization. Blanchard’s experience is expected to help the firm move from development to broader market adoption.